Profile data is unavailable for this security.
About the company
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
- Revenue in USD (TTM)1.62bn
- Net income in USD-204.35m
- Incorporated2008
- Employees1.15k
- Locationargenx SELaarderhoogtweg 25AMSTERDAM 1101 EBNetherlandsNLD
- Phone+31 763030
- Websitehttps://www.argenx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Moderna Inc | 5.05bn | -5.87bn | 23.14bn | 5.60k | -- | 1.97 | -- | 4.58 | -15.37 | -15.37 | 13.21 | 30.50 | 0.2689 | 3.12 | 25.57 | 901,785.70 | -31.24 | 20.95 | -36.58 | 29.51 | 65.60 | -- | -116.18 | 32.10 | 3.92 | -- | 0.0469 | 0.00 | -64.45 | 119.28 | -156.37 | -- | 46.22 | -- |
ICON PLC | 8.33bn | 714.43m | 24.31bn | 41.10k | 34.11 | 2.54 | 18.57 | 2.92 | 8.60 | 8.60 | 100.31 | 115.74 | 0.489 | -- | 3.01 | 202,722.40 | 4.19 | 3.93 | 5.00 | 4.80 | 29.75 | 28.91 | 8.57 | 7.37 | -- | 3.86 | 0.264 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
argenx SE - ADR | 1.62bn | -204.35m | 31.69bn | 1.15k | -- | 7.43 | -- | 19.62 | -3.48 | -3.48 | 27.43 | 71.28 | 0.4043 | 0.6484 | 3.94 | 1,407,023.00 | -5.11 | -17.65 | -5.70 | -19.79 | 89.41 | -- | -12.65 | -97.72 | 7.88 | -- | 0.0079 | -- | 198.56 | 117.25 | 58.42 | -- | 122.32 | -- |
Alnylam Pharmaceuticals, Inc. | 2.34bn | -72.94m | 34.40bn | 2.10k | -- | -- | -- | 14.68 | -0.6285 | -0.6285 | 18.39 | -0.024 | 0.6326 | 3.31 | 158.02 | 1,116,384.00 | -1.97 | -26.56 | -2.62 | -32.77 | 87.00 | 83.66 | -3.11 | -94.26 | 2.93 | 0.6753 | 1.00 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
Iqvia Holdings Inc | 15.16bn | 1.42bn | 41.90bn | 88.00k | 29.82 | 6.24 | 16.30 | 2.76 | 7.71 | 7.71 | 82.07 | 36.83 | 0.5781 | -- | 4.74 | 174,195.40 | 5.44 | 3.24 | 7.26 | 4.07 | 35.10 | 34.32 | 9.40 | 6.03 | -- | 3.27 | 0.6638 | 0.00 | 3.98 | 7.55 | 24.47 | 43.39 | 7.17 | -- |
Holder | Shares | % Held |
---|---|---|
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 5.09m | 8.56% |
Artisan Partners LPas of 31 Mar 2024 | 3.19m | 5.37% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 3.08m | 5.18% |
Janus Henderson Investors US LLCas of 31 Mar 2024 | 2.20m | 3.71% |
T. Rowe Price Investment Management, Inc.as of 31 Mar 2024 | 2.12m | 3.56% |
Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 1.86m | 3.14% |
Avoro Capital Advisor LLCas of 31 Mar 2024 | 1.24m | 2.08% |
Bellevue Asset Management AGas of 31 Mar 2024 | 811.02k | 1.37% |
RTW Investments LPas of 31 Mar 2024 | 667.20k | 1.12% |
ClearBridge Investments LLCas of 31 Mar 2024 | 596.28k | 1.00% |